Karyopharm Therapeutics Inc.
KPTI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001503802
In the last 90 days, Karyopharm Therapeutics Inc. insiders filed 0 open-market purchases and 2 sales; 96 institutions reported holding it in 13F filings for Q2 2026, worth $206.8M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Karyopharm Therapeutics Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 2 insiders, $1.38K in total
- Insiders trading
- 2
- Net value
- −$1.38K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Karyopharm Therapeutics Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Abate Kristin | Chief Accounting Officer | 23,782 | Sep 2, 2026 | 7 |
| Poulton Stuart | EVP, Chief Development Officer | 94,632 | Jul 30, 2026 | 6 |
| Bohlin Garen G | Director | 18,517 | May 26, 2026 | 1 |
| Pakianathan Deepika | Director | 15,508 | May 26, 2026 | 1 |
| Greene Barry E | Director | 16,415 | May 26, 2026 | 1 |
| Schor Chen | Director | 15,508 | May 26, 2026 | 1 |
| Oliger Christy J. | Director | 15,508 | May 26, 2026 | 1 |
| Su Zhen | Director | 15,508 | May 26, 2026 | 1 |
| Paulson Richard A. | President and CEO | 269,747 | May 15, 2026 | 4 |
| Rangwala Reshma | EVP & Chief Medical Officer | 56,829 | May 15, 2026 | 4 |
| Mano Michael | EVP, CLO&Secretary | 94,398 | May 15, 2026 | 4 |
| Cheng Sohanya Roshan | EVP & Chief Commercial Officer | 107,940 | May 15, 2026 | 4 |
| Macomber Lori | EVP, CFO & Treasurer | 85,105 | Feb 4, 2026 | 3 |
| Mirza Mansoor Raza | Director | – | May 29, 2025 | 0 |
| Mason Michael | EVP, CFO & Treasurer | 391,054 | Sep 5, 2024 | 0 |
| Honig Peter | Director | – | May 25, 2023 | 0 |
| Mitchener Stephen | SVP, Chief Business Officer | 128,313 | Mar 2, 2023 | 0 |
| Shacham Sharon | Chief Scientific Officer | 958,131 | Mar 31, 2022 | 0 |
| Kauffman Michael | Director | 898,131Indirect | Mar 2, 2022 | 0 |
| Frenkel Ran | EVP, Chief Dev. Officer | 168,290 | Mar 2, 2022 | 0 |
| Shah Jatin | EVP, Chief Medical Officer | 129,450 | Feb 22, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 5, 2022 (view filing) | Oct 4 | 1 day | Paulson Richard A.President and CEO | SSale | −3.49K | $5.87 | −$20.5K | −0.6%619.5K after | |
| Sep 9, 2022 (view filing) | Sep 8 | 1 day | Paulson Richard A.President and CEO | SSale | −3.48K | $5.23 | −$18.2K | −0.6%623.0K after | 2 lots |
| Aug 5, 2022 (view filing) | Aug 4 | 1 day | Paulson Richard A.President and CEO | SSale | −2.31K | $4.48 | −$10.4K | −0.4%626.5K after | |
| Jul 11, 2022 (view filing) | Jul 8 | 3 days | Paulson Richard A.President and CEO | SSale | −2.12K | $5.18 | −$11.0K | −0.3%628.8K after | |
| Jun 14, 2022 (view filing) | Jun 13 | 1 day | Cheng Sohanya RoshanChief Commercial Officer | SSale | −1.55K | $5.21 | −$8.08K | −1.7%89.9K after | 2 lots |
| Jun 10, 2022 (view filing) | Jun 8-10 | 2 days | Pakianathan DeepikaDirector | SSale | −538.8K | $6.37 | −$3.43M | −97.0%16.7K after | 6 lots |
| Jun 8, 2022 (view filing) | Jun 7 | 1 day | Paulson Richard A.President and CEO | SSale | −2.54K | $5.76 | −$14.6K | −0.4%630.9K after | |
| Jun 6, 2022 (view filing) | Jun 3 | 3 days | Mason MichaelEVP, CFO, Treasurer | SSale | −601 | $6.04 | −$3.63K | −0.4%138.5K after | 2 lots |
| May 5, 2022 (view filing) | May 4 | 1 day | Paulson Richard A.President and CEO | SSale | −28.5K | $6.23 | −$177.6K | −4.3%633.4K after | 2 lots |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Frenkel RanEVP, Chief Dev. Officer | SSale | −1.66K | $10.24 | −$17.0K | −1.0%168.3K after | |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Mason MichaelEVP, CFO & Treasurer | SSale | −2.40K | $10.24 | −$24.6K | −1.7%139.1K after | |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Shacham SharonChief Scientific Officer | SSale | −6.23K | $10.24 | −$63.8K | −0.7%898.1K after | Duplicate filing |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Shacham SharonChief Scientific Officer | SSale | −6.23K | $10.24 | −$63.8K | −0.9%713.8K after | Duplicate filing |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Kauffman MichaelDirector | SSale | −6.23K | $10.24 | −$63.8K | −0.9%713.8K after | |
| Mar 2, 2022 (view filing) | Feb 28 | 2 days | Kauffman MichaelDirector | SSale | −6.23K | $10.24 | −$63.8K | −0.7%898.1K after | |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Shah JatinEVP, Chief Medical Officer | SSale | −1.31K | $12.12 | −$15.8K | −1.0%129.4K after | |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Frenkel RanEVP, Chief Dev. Officer | SSale | −2.93K | $12.12 | −$35.5K | −2.8%101.7K after | |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Shacham SharonChief Scientific Officer | SSale | −9.09K | $12.12 | −$110.1K | −1.0%904.4K after | Duplicate filing |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Shacham SharonChief Scientific Officer | SSale | −9.08K | $12.12 | −$110.0K | −1.3%699.0K after | Duplicate filing |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Kauffman MichaelDirector | SSale | −9.08K | $12.12 | −$110.0K | −1.3%699.0K after | |
| Feb 22, 2022 (view filing) | Feb 17 | 5 days | Kauffman MichaelDirector | SSale | −9.09K | $12.12 | −$110.1K | −1.0%904.4K after | |
| Feb 9, 2022 (view filing) | Feb 7 | 2 days | Shah JatinEVP, Chief Medical Officer | SSale | −1.70K | $9.86 | −$16.8K | −1.3%130.8K after | |
| Feb 9, 2022 (view filing) | Feb 7 | 2 days | Frenkel RanEVP, Chief Dev. Officer | SSale | −1.99K | $9.86 | −$19.6K | −1.9%104.6K after | |
| Feb 9, 2022 (view filing) | Feb 7 | 2 days | Mason MichaelEVP, CFO & Treasurer | SSale | −3.95K | $9.86 | −$38.9K | −6.9%53.3K after | |
| Feb 9, 2022 (view filing) | Feb 7 | 2 days | Kauffman MichaelDirector | SSale | −6.76K | $9.86 | −$66.7K | −0.9%708.1K after | Duplicate filing |
| Feb 9, 2022 (view filing) | Feb 7 | 2 days | Kauffman MichaelDirector | SSale | −6.71K | $9.86 | −$66.1K | −0.7%913.4K after | Duplicate filing |
| Feb 9, 2022 (view filing) | Feb 7 | 2 days | Shacham SharonChief Scientific Officer | SSale | −6.71K | $9.86 | −$66.1K | −0.7%913.4K after | |
| Feb 9, 2022 (view filing) | Feb 7 | 2 days | Shacham SharonChief Scientific Officer | SSale | −6.76K | $9.86 | −$66.7K | −0.9%708.1K after | |
| Dec 3, 2021 (view filing) | Dec 2 | 1 day | Mitchener StephenSVP, Chief Business Officer | SSale | −499 | $6.69 | −$3.34K | −13.1%3.30K after |